Research on a bacterial toxin first discovered in Adelaide has led to the development a new blood test for the early diagnosis of ovarian cancer.
AstraZeneca and MSD’s Lynparza is a step closer to being cleared in Europe as maintenance therapy for some patients with ovarian cancer.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.
Copyright © 2016-2018 Drugdu.com. All Rights Reserved.